ArrayExpress Uploader0humanmyometriumnannon-t(12;14) fibroid tumornot specifiedt(12;14) fibroid tumor100myometriumnannon-t(12;14) fibroid tumornot specifiedt(12;14) fibroid tumor30myometriumnannon-t(12;14) fibroid tumor7t(12;14) fibroid tumor16myometriumnannon-t(12;14) fibroid tumor4t(12;14) fibroid tumor100myometriumnannon-t(12;14) fibroid tumornot specifiedt(12;14) fibroid tumor48myometriumnannon-t(12;14) fibroid tumor5t(12;14) fibroid tumor30myometriumnannon-t(12;14) fibroid tumor3t(12;14) fibroid tumor63myometriumnannon-t(12;14) fibroid tumor8t(12;14) fibroid tumor77myometriumnannon-t(12;14) fibroid tumor4t(12;14) fibroid tumor833412arrayexpress_sid4Uterine leiomyomata (UL), the most common neoplasm in reproductive age women, have recurrent cytogenetic abnormalities including...E-GEOD-18096/profile/8773/arrayexpressuploader227myometriumDec.12, 2014Falseidentifying-the-molecular-signature-of-the-t1214-sE-GEOD-18096_A-AFFY-44Identifying the molecular signature of the t(12;14) subgroup of uterine leiomyomata using a paired analysisSep.15, 2014Uterine leiomyomata (UL), the most common neoplasm in reproductive age women, have recurrent cytogenetic abnormalities including t(12;14). To develop a molecular signature, matched t(12;14) and non-t(12;14) tumors identified by FISH or karyotyping from each of 9 women were profiled using Affymetrix GeneChip U133 Plus 2.0 oligonucleotide arrays. Model analysis demonstrated the necessity for a matched design to eliminate the confounding effect of genotype and environment that underlay patient to patient variation. Matched myometrium, t(12;14) fibroid tumors and non-t(12;14) fibroid tumors identified by FISH or karyotyping from each of 9 women were profiled using Affymetrix GeneChip U133 Plus 2.0 oligonucleotide gene expression arrays.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-18096http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-18096/samples/